CLIFF (Cordlife Group) Research & Development: $0.00 Mil (TTM As of Mar. 2026)


CLIFF Cordlife Group Ltd CLIFF
33 GF Score
Price $0.15
GF Value $0.08
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cordlife Group Research & Development?

Cordlife Group CLIFF 33 Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cordlife Group's Research & Development for the three months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Cordlife Group  (OTCPK:CLIFF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cordlife Group Research & Development Related Terms

Cordlife Group Research & Development Historical Data

* Premium members only.

The historical data trend for Cordlife Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cordlife Group Research & Development Chart

Cordlife Group Annual Data
Trend Jun15 Jun16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cordlife Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CLIFF
33GF Score
Cordlife Group Ltd CLIFF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cordlife Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
Cordlife Group (CLIFF) has a Research & Development of $0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Cordlife Group and its competitors.
Is Cordlife Group's Research & Development too high?
Cordlife Group's current Research & Development is $0.00 Mil. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Research & Development compare to TMO and DHR?
Cordlife Group's Research & Development of $0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cordlife Group and its competitors. Cordlife Group's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.15 — trading 88.1% above its estimated fair value. The current Research & Development is $0.00 Mil. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cordlife Group (CLIFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cordlife Group stock appears to be overvalued. The current stock price of $0.15 is trading 88.1% above its estimated GF Value™ of $0.08. GuruFocus considers Cordlife Group to be Significantly Overvalued.

Key valuation signals for CLIFF:

  • Research & Development: $0.00 Mil
  • GF Value™: $0.08 vs. price of $0.15 (88.1% above fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cordlife Group Business Description

Other Exchanges P8A:Singapore
Address 1 Kim Seng Promenade, No. 15-01, Great World City East, Singapore, SGP, 237994
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
33GF Score

Get the complete analysis for CLIFF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.08
GF Value